The Eye Center of Texas has become one of the first practices in the United States to offer Epioxa, a newly FDA-approved epithelium-on corneal cross-linking therapy for keratoconus, with treatments launching April 2026 at its Bellaire location.

Yasir Ahmed is the first physician in Texas to provide the procedure, marking an early rollout of the next-generation technology developed by Glaukos. Unlike traditional “epi-off” cross-linking, which requires removal of the corneal epithelium, Epioxa preserves the outer layer of the cornea, aiming to reduce patient discomfort, shorten recovery time, and minimize complications.

Keratoconus is a progressive condition that typically emerges in adolescence, causing the cornea to thin and bulge into a cone-like shape, leading to distorted vision. While glasses and contact lenses can manage symptoms, corneal cross-linking is designed to slow or halt disease progression. Without intervention, up to 20 percent of patients may eventually require corneal transplantation.

Epioxa uses bioactivated riboflavin drops in combination with UV light to strengthen corneal collagen while maintaining epithelial integrity. Clinical trial data cited by the company indicate improved corneal stability in treated patients, with particularly strong effects observed in individuals aged 13 to 28.

Ahmed, a fellowship-trained cornea specialist, said the approach enables more efficient treatment while improving the patient experience. “By keeping the outer layer of the cornea intact, Epioxa is designed to improve patient comfort, simplify the treatment process and support a quicker recovery,” he noted. “This approach allows us to treat patients more efficiently and help stop progression, so they can maintain their vision and stay focused on their daily lives.”

The introduction of Epioxa reflects a broader shift toward less invasive cross-linking techniques as clinicians seek earlier and more patient-friendly interventions for keratoconus management.

Source: Eye Center of Texas.